ARK Genomic Revolution ET... (ARKG)
CBOE: ARKG
· Real-Time Price · USD
29.82
0.97 (3.36%)
At close: Oct 02, 2025, 3:59 PM
3.36% (1D)
| Bid | 29.8 |
| Market Cap | 1.1B |
| AUM | 1.03B |
| NAV | 27.29 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 36.96M |
| Inception Date | Oct 30, 2014 |
| Ask | 29.88 |
| Volume | 2,523,785 |
| Open | 29.14 |
| Previous Close | 28.85 |
| Day's Range | 28.92 - 29.82 |
| 52-Week Range | 17.50 - 31.16 |
| Holdings | 50 |
| Expense Ratio | 0.75% |
About ARKG
ARKG is an actively managed Exchange Traded Fund (ETF) that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors that are relevant to the Fund’s investment theme of the genomics revolution.
Asset Class Equity
Ticker Symbol ARKG
Inception Date Oct 30, 2014
Provider ARK
Website Fund Home Page
Exchange CBOE
Top 10 Holdings 55.40% of assets
| Name | Symbol | Weight |
|---|---|---|
| Tempus Ai, Inc. | TEM | 10.44% |
| Crispr Therapeutics ... | CRSP | 9.98% |
| Twist Bioscience Cor... | TWST | 4.96% |
| Recursion Pharmaceut... | RXRX | 4.90% |
| Personalis, Inc. | PSNL | 4.48% |
| Guardant Health, Inc... | GH | 4.41% |
| Intellia Therapeutic... | NTLA | 4.24% |
| Beam Therapeutics In... | BEAM | 4.12% |
| Natera, Inc. | NTRA | 4.06% |
| Adaptive Biotechnolo... | ADPT | 3.81% |
Dividends Dividend Yield 0.64%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 29, 2021 | $0.3824 | Dec 31, 2021 |
| Dec 29, 2020 | $0.7901 | Dec 31, 2020 |
| Dec 27, 2019 | $1.0539 | Dec 31, 2019 |
| Dec 27, 2018 | $0.4663 | Dec 31, 2018 |
| Dec 27, 2017 | $0.3277 | Dec 29, 2017 |
2 months ago · seekingalpha.com
ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still SoftI reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward...